Immunocore presents Kimmtrak data showing doubled five-year survival rate in metastatic uveal melanoma
IMCR•Immunocore presented data showing a doubled five-year survival rate in metastatic uveal melanoma. KIMMTRAK combined with brenetafusp had a 29% response rate among 17 previously untreated patients, with survival rates of 88% at one year and 70% at two years.
1. Combination results
KIMMTRAK combined with brenetafusp produced a 29% response rate in 17 previously untreated patients with metastatic uveal melanoma. Overall survival rates were 88% at one year and 70% at two years.
2. Other trial updates
Immunocore reported KIMMTRAK net sales of $325 million for January through September 2026, up 10% year over year. The Phase 3 TEBE-AM cutaneous melanoma trial completed enrollment of 540 patients, with topline data expected in the second quarter of 2027; a randomized Phase 2/3 DUET-UVEAL trial of the combination is planned.
